Vaccine: X最新文献

{"title":"Misconceptions leading to human papillomavirus vaccination hesitancy in Nigeria: Findings from a modified Delphi panel with stakeholders of the immunization ecosystem","authors":"Mohammed Mohammed Manga ,&nbsp;Adeola Fowotade ,&nbsp;Zara Isah Modibbo ,&nbsp;Mashudu Madhivhandila ,&nbsp;Tidiane Ndao ,&nbsp;Olufemi Abayomi ,&nbsp;Yahaya Mohammed","doi":"10.1016/j.jvacx.2025.100729","DOIUrl":"10.1016/j.jvacx.2025.100729","url":null,"abstract":"<div><h3>Background</h3><div>Human papilloma virus (HPV) is a significant contributor to various cancers, notably cervical cancer, which poses a major health challenge in sub-Saharan Africa (SSA), including Nigeria. Despite the availability and effectiveness of HPV vaccines, many SSA countries have yet to reach the World Health Organization's vaccination goals. Nigeria introduced the HPV vaccine for girls (9–14 years) as part of the national immunization program in October 2023. This was heralded with certain misconceptions among both healthcare workers and the general populace. This study aimed to identify and rank these misconceptions via the modified Delphi technique to increase HPV vaccination coverage in Nigeria.</div></div><div><h3>Objectives</h3><div>The primary objective of this study was to identify and rank predominant HPV vaccine misconceptions in Nigeria, summarize the stability of expert judgments across rounds and to translate the prioritized list into communication and training recommendations.</div></div><div><h3>Methods</h3><div>We conducted desk review, expert validation and a two-round modified Delphi with immunization stakeholders from across Nigeria's 36 states and the Federal Capital Territory. Thirteen candidate misconceptions were generated from desk review and validation meetings, then rated on a five-point Likert “criticality” scale reflecting perceived prevalence, barrier importance, and likely impact on uptake if unaddressed. Descriptive statistics summarized item rankings and round-to-round changes; a paired <em>t</em>-test assessed aggregate stability.</div></div><div><h3>Results</h3><div>Forty-nine panelists completed both rounds. Rank order at the top was stable: the infertility/population-control misconception consistently ranked first, followed by the belief that vaccination promotes adolescent promiscuity, safety/“Western conspiracy” and “unknown long-term side-effects” clustered next. Aggregate ratings did not change significantly between rounds (paired <em>t</em>-test t (8) = 0.39, <em>p</em> = 0.71).</div></div><div><h3>Conclusion</h3><div>The stability of ratings between rounds indicate that observed differences were compatible with random variation rather than systematic shifts in opinion. A decision-ready prioritization of HPV vaccine misconceptions highlights a set of high-level misconceptions, like infertility, promiscuity, and safety/conspiracy narratives that should anchor first-wave communication in Nigeria.</div><div>Programs can translate these findings into audience-specific strategies like caregiver and community‑leader engagement with clear, safety-affirming messages, brief provider scripts and micro-training for school and clinic encounters and concise briefs for local decision-makers. Future iterations should pre-specify formal consensus thresholds and incorporate public prevalence measures to refine priority setting.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"27 ","pages":"Article 100729"},"PeriodicalIF":2.2,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145110001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of the TBE vaccination program in the Åland Islands","authors":"Tove Hoffman ,&nbsp;Bo Albinsson ,&nbsp;Linda Kolstad ,&nbsp;Marika Nordberg ,&nbsp;Sirkka Vene ,&nbsp;Patrik Ellström ,&nbsp;Bengt Rönnberg ,&nbsp;Olli Vapalahti ,&nbsp;Dag Nyman ,&nbsp;Åke Lundkvist","doi":"10.1016/j.jvacx.2025.100727","DOIUrl":"10.1016/j.jvacx.2025.100727","url":null,"abstract":"<div><h3>Background</h3><div>The Åland Islands included tick-borne encephalitis (TBE) vaccination in the general vaccination program in 2006.</div></div><div><h3>Aim</h3><div>Investigate the effect of the vaccination on the number of reported TBE cases and the TBEV IgG seroprevalence in blood donors in the Åland Islands.</div></div><div><h3>Methods</h3><div>We used reported data on TBE cases (1995–2018) and sera collected from blood donors in 1995 (<em>n</em> = 300) and 2018 (<em>n</em> = 300). Samples were analyzed by a Luminex-based method that can differentiate antibodies induced by a TBE virus (TBEV) infection from those produced after TBE vaccination.</div></div><div><h3>Results</h3><div>A weak negative trend but no significant relationship between the number of reported TBE cases and year was observed. Of the blood donors, 3.3 % and 7.0 % tested positive for a previous TBEV infection in 1995 and 2018, respectively. There was no significant difference between the blood donor cohorts regarding the number of TBEV-infected and non-infected individuals. The proportion of TBE vaccinated blood donors increased from 2.7 % in 1995 to 81.0 % in 2018. The proportion of previously TBEV-infected unvaccinated blood donors increased from 3.4 % in 1995 to 36.8 % in 2018. The estimated number of unvaccinated individuals decreased 3.8-fold from 1995 to 2018. The rate of TBE cases in the estimated unvaccinated population increased 3.9-fold between the years 1995 and 2018. The risk of being infected by TBEV tended to be higher in 2018, reduced for men, and to increase with age.</div></div><div><h3>Conclusion</h3><div>The strong increase in seroprevalence of anti-NS1 antibodies and increase of TBE cases in the estimated unvaccinated population seen in this study suggest that the low number of TBE cases in the Åland Islands is explained by the high vaccination coverage, suggesting a positive effect of the free TBE vaccination on public health in the Åland Islands.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"27 ","pages":"Article 100727"},"PeriodicalIF":2.2,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145118942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors associated with youth vaccine acceptance during the COVID-19 pandemic: Coordinated analyses across 5 Canadian datasets","authors":"M.E. Ames ,&nbsp;C.A. Sierra Hernandez ,&nbsp;A.F. Chung ,&nbsp;H. Elgharbawy ,&nbsp;T.O. Afifi ,&nbsp;S. Craig ,&nbsp;C.A. McMorris ,&nbsp;H. Samji ,&nbsp;K.D. Schwartz ,&nbsp;S.E. Stewart ,&nbsp;B. Turner ,&nbsp;T.P. Paterson ,&nbsp;The Youth Vaccine Confidence Team","doi":"10.1016/j.jvacx.2025.100726","DOIUrl":"10.1016/j.jvacx.2025.100726","url":null,"abstract":"<div><div>Vaccines are essential for preventing infectious diseases, yet vaccine hesitancy—particularly among youth—remains a growing concern. This study investigated factors influencing COVID-19 vaccine acceptance among Canadian youth (aged 12–29 years) across three pandemic stages using data from five rapid-response surveys. Multivariable logistic regression analyses identified sociodemographic, pandemic-related impacts, and mental health factors associated with vaccine acceptance. Results showed increasing vaccine acceptance over time across samples (i.e., Stage 1: 52.3 %–65.4 %; Stage 2: 73.8 %–83.2 %; and, Stage 3: 85.3 %–96.0 %). Although findings varied across samples, overall, parental education (significant adjusted odds ratios [aOR] range across samples and Stages = 0.16 to 2.07), living area (i.e., rural/urban; aORs range = 2.07 to 2.18), and COVID-19 stress (aOR range = 1.06 to 2.34) emerged as consistent factors across time. Other factors, such as being older (Stage 1 aOR = 1.15 to 3.21; Stage 3 aOR = 0.58), White (Stage 1 aOR = 1.55 to 1.69; Stage 2 aOR = 1.48), female (Stage 1 a OR = 0.60 to 0.72) or having a family member diagnosed with COVID-19 (Stage 1 aOR = 1.89; Stage 2 aOR = 0.55; Stage 3 aOR = 0.52) appeared as potential context-specific factors related to vaccine acceptance. Mental health had limited influence. These findings underscore the need for targeted vaccination campaigns addressing stable and dynamic sociodemographic and stress-related factors among youth.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"27 ","pages":"Article 100726"},"PeriodicalIF":2.2,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145118945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cross-country analysis on HPV vaccination behaviors among health workers and parents: a qualitative report from seven middle-income countries","authors":"Gulaiim Almatkyzy ,&nbsp;Sahil Khan Warsi ,&nbsp;Siff Malue Nielsen ,&nbsp;Brett J. Craig","doi":"10.1016/j.jvacx.2025.100725","DOIUrl":"10.1016/j.jvacx.2025.100725","url":null,"abstract":"<div><h3>Purpose</h3><div>This article presents a cross-country analysis of qualitative research reports on the barriers and drivers of HPV vaccination-related behavior among parents and health workers in seven middle-income countries using the COM-B theoretical framework. Four reports are from countries that had already introduced the HPV vaccine — Georgia, Moldova, Turkmenistan, and Uzbekistan, while the other three reports are from Kazakhstan, Kosovo, and Tajikistan which were preparing for HPV vaccine introduction in 2023 and 2024.</div></div><div><h3>Results</h3><div>The cross-country analysis revealed that health workers (HWs), especially specialists like gynecologists and oncologists, were viewed as trusted sources of vaccination information by both parents and HWs. However, HWs faced gaps in HPV vaccine knowledge and communication skills, and these gaps persisted in some form even after training was conducted in countries that had already introduced the HPV vaccine. In addition, these specialists were not always included when training sessions were conducted with family doctors and nurses in preparation for the vaccine's introduction. Parents also experience knowledge gaps, safety concerns, and lack of trust. Parents across countries shared concerns related to HPV vaccine safety and effectiveness and were often exposed to misconceptions or misinformation through media and social networks. This was compounded by the lack of a strong and confident recommendation from HWs and poor patient-provider communication.</div></div><div><h3>Conclusions</h3><div>The analyzed reports highlighted the need for tailored, multi-faceted interventions that account for locally specific issues, influencers, and target groups. Two prominent recommendations posited in the reports were: 1) engaging parents and addressing their concerns at the community level, and 2) ensuring HPV vaccine confidence through HW training and engagement, especially for specialists, and providing access to evidence-based information for HWs and others who influence vaccine acceptance.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"27 ","pages":"Article 100725"},"PeriodicalIF":2.2,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145107531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A natural oil-based nanoadjuvant enhances the immunogenicity of enterotoxigenic Escherichia coli (ETEC) in an experimental vaccine","authors":"María Eugenia Cecchini ,&nbsp;Sofía Arsaute ,&nbsp;Ivana Dalila Montironi ,&nbsp;Dardo Andrés Roma ,&nbsp;José Raviolo ,&nbsp;Federico Ruiz Moreno ,&nbsp;Belkys Maletto ,&nbsp;Nahuel Matías Camacho ,&nbsp;Fernando Javier Mañas ,&nbsp;Romina Valeria Bellingeri ,&nbsp;Laura Noelia Cariddi","doi":"10.1016/j.jvacx.2025.100724","DOIUrl":"10.1016/j.jvacx.2025.100724","url":null,"abstract":"<div><div>Enterotoxigenic <em>Escherichia coli</em> (ETEC) is the leading cause of post-weaning diarrhea in piglets. The development of novel adjuvanted vaccines that can be administered directly to piglets remains a priority for the swine industry. <em>Minthostachys verticillata</em> essential oil (EO) has shown adjuvant effects, but its poor stability and solubility limit its use, that could be solved by emulsification. This study aimed to evaluate the effect of an EO-based nanoadjuvant to enhance the immunogenicity of ETEC in an experimental vaccine using mice as a preliminary model. A nanoemulsion (NEO) was formulated with EO (20 % v/v), Tween 80 (0.75 % v/v), and Span 60 (0.25 % w/v) using a high-energy method. The interaction between NEO and ETEC was analyzed by a scanning electron microscope. Experimental vaccines were prepared with inactivated ETEC strain combined with NEO (0.5, 0.75, and 1 mg/mL of EO) or EO (1 mg/mL) as adjuvants. Controls included Incomplete Freund's Adjuvant (IFA), Tween 80/Span 60 as a vehicle control, saline, and non-adjuvanted formulations. Balb/c mice were subcutaneously injected with the experimental vaccines, with four doses administered every 14 days. Antigen-specific antibody titers (IgG, IgG1, IgG2a), opsonizing capacity, and CD4⁺/CD69⁺ and CD8⁺/CD69⁺ T cells activation were evaluated. Splenic mononuclear cell proliferation and cytokine production (IFN-γ and IL-10) were also measured. Hepatic enzyme levels and malondialdehyde (MDA) concentrations were assessed to evaluate toxicity. NEO induced anti-ETEC IgG with significant opsonizing potential, increase in the percentage of CD4⁺/CD69⁺ and CD8⁺/CD69⁺ T cells, and production of IFN-γ. It caused no local reactogenicity, did not alter hepatic enzyme levels, and did not increase MDA concentrations. In conclusion, NEO demonstrated adjuvant potential, activating both humoral and cellular immune responses against ETEC without evidence of toxicity.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"27 ","pages":"Article 100724"},"PeriodicalIF":2.2,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145107623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 Vaccine Hesitancy Scale: Psychometric properties and validation among pregnant and breastfeeding persons and parents","authors":"Heidi Sze Lok Fan ,&nbsp;Edmond Pui Hang Choi ,&nbsp;Elizabeth Keys ,&nbsp;Rishma Chooniedass ,&nbsp;Stephanie Masina ,&nbsp;Alex Halonen ,&nbsp;Kalysse Mantai ,&nbsp;Marie Tarrant","doi":"10.1016/j.jvacx.2025.100720","DOIUrl":"10.1016/j.jvacx.2025.100720","url":null,"abstract":"<div><h3>Introduction</h3><div>The Vaccine Hesitancy Scale (VHS) was developed by the World Health Organization's Strategic Advisory Group of Experts on Immunization (SAGE) to examine parents' vaccine hesitancy toward childhood vaccines. The VHS has been validated and modified to assess vaccine hesitancy toward specific vaccines, including influenza and human papillomavirus vaccines, but not the COVID-19 vaccine. The objective of this study is to validate a modified VHS for the COVID-19 vaccine among pregnant and breastfeeding persons, and parents of children under 12 years of age.</div></div><div><h3>Methods</h3><div>A cross-sectional survey was conducted in British Columbia, Canada from October to December 2021. A total of 1510 participants including pregnant and breastfeeding persons, and parents of children &lt;12 years of age were included in the analysis. Participants completed questionnaires tailored to their respective groups based on self-identification. Confirmatory factor analysis was conducted to assess the original VHS structure. The data were then randomly split into training and validation sets for exploratory and confirmatory factor analyses. Factor structure, internal construct validity, internal consistency, and known-group validity were evaluated.</div></div><div><h3>Results</h3><div>The original VHS model showed a poor fit. Exploratory factor analysis identified a revised one-factor model (VHS-COVID19), which showed satisfactory fit in the validation sample for pregnant participants (comparative fit index [CFI] = 0.999; root mean square error of approximation [RMSEA] = 0.041; standardized root mean squared residual [SRMR] = 0.008; Tucker-Lewis Index [TLI] = 0.997), breastfeeding participants (CFI = 0.995; RMAEA = 0.089; SRMR = 0.006; TLI = 0.990) and parent participants (CFI = 0.995; RMAEA = 0.080; SRMR = 0.004; TLI = 0.992). The revised scale comprised five items for pregnant and breastfeeding participants and six for parent participants<em>.</em> VHS-COVID19 showed high internal construct validity and reliability.</div></div><div><h3>Conclusions</h3><div>The VHS-COVID19 shows adequate psychometric performance for assessing COVID-19 vaccine hesitancy among pregnant, breastfeeding persons, and parents. It is easy to administer and can be used by healthcare providers to rapidly assess vaccine hesitancy of the targeted population in clinical settings.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"27 ","pages":"Article 100720"},"PeriodicalIF":2.2,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145107626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential health impact and cost-effectiveness of human papillomavirus vaccination in Tunisia: A comparative modeling study","authors":"Oumaima Laraj ,&nbsp;Beya Benzina ,&nbsp;Ahlem Gzara ,&nbsp;Amira Kebir ,&nbsp;Kaja Abbas ,&nbsp;Slimane BenMiled","doi":"10.1016/j.jvacx.2025.100712","DOIUrl":"10.1016/j.jvacx.2025.100712","url":null,"abstract":"<div><h3>Background:</h3><div>Cervical cancer is one of the most prevalent cancers affecting women especially in low- and middle income countries and is caused by persistent infection with human papillomavirus (HPV). HPV vaccination can significantly reduce the cervical cancer burden. However, HPV vaccination is not yet included in the Tunisian immunization program. To inform decision-making on HPV vaccine introduction in Tunisia, we conducted a comparative modeling study to project the health impact and cost-effectiveness of four HPV vaccines (Cecolin, Cervarix, Gardasil, 4, and Gardasil-9) targeted to 12-year-old girls in 2025.</div></div><div><h3>Methods:</h3><div>We used two static cohort models (UNIVAC and Papillomavirus Rapid Interface for Modeling and Economics (PRIME)) to estimate the health and economic impact of HPV vaccination from the health system and societal perspectives. Our data inputs to the model include demography and cervical cancer burden as well as unit costs for treatment, vaccines, and vaccine delivery. We estimated health impact in terms of cases, deaths, and disability-adjusted life years (DALYs) averted by HPV vaccination, and economic impact in terms of vaccination costs, treatment costs saved, net cost, and incremental cost-effectiveness ratios (ICERs).</div></div><div><h3>Results:</h3><div>We estimated that Cecolin is the most cost-effective HPV vaccine in Tunisia, particularly when cross-protection is considered. Despite Cervarix offering greater health benefits of 70% versus 62% reductions in cervical cancer cases and deaths at 87% coverage, Cecolin has lower net costs and is more favorable across different willingness-to-pay (WTP) thresholds. At a WTP of USD 1169 per DALY averted (30% of Tunisia’s GDP per capita), Cecolin and Cervarix demonstrate similar probabilities of being cost-effective.</div></div><div><h3>Conclusion:</h3><div>Based on the vaccine impact estimates generated by the UNIVAC and PRIME models, we inferred that the four HPV vaccines (Cecolin, Cervarix Gardasil,4, and Gardasil-9) were cost-effective in the Tunisian context. This evidence is useful to inform HPV vaccine introduction in Tunisia.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"27 ","pages":"Article 100712"},"PeriodicalIF":2.2,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145050302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Durability of neutralizing antibody and T-cell responses in COVID-19 patients after infection and booster vaccination","authors":"Lin Yao ,&nbsp;Xiao-Lin Jiang ,&nbsp;Jun-Xia Cao ,&nbsp;Qiang Guo ,&nbsp;Meng-Na Wu ,&nbsp;Shu-Zhi Wu ,&nbsp;Li-Jun Duan ,&nbsp;Yuan Shen ,&nbsp;Bing-Dong Zhan ,&nbsp;Jun-Fen Lin ,&nbsp;Ming-Dong Jiang ,&nbsp;Hong-Hong Peng ,&nbsp;Yu-Wei Zhang ,&nbsp;Guo-Jian Yang ,&nbsp;Xue-Dong Song ,&nbsp;Chao Shi ,&nbsp;Ji-Yan Zhang ,&nbsp;Wen-Guo Jiang ,&nbsp;Mai-Juan Ma","doi":"10.1016/j.jvacx.2025.100718","DOIUrl":"10.1016/j.jvacx.2025.100718","url":null,"abstract":"<div><div>Determining the durability of immunity after SARS-CoV-2 infection or vaccination is critical for understanding immune protection upon reinfection and optimizing vaccine design. We measured SARS-CoV-2-specific antibodies and T-cell responses in COVID-19 convalescent patients up to 14 months after infection and COVID-19 convalescents who received two doses of BBIBP-CorV at 6-month intervals. We observed that most convalescents had durable neutralizing antibody and T-cell responses against the SARS-CoV-2 Wuhan strain at least 14 months after infection. Administering a booster dose to convalescent patients significantly increased neutralizing antibodies against the Wuhan strain, but neutralization activity against Omicron BA.1, BA.2, BA.2.12.1, and BA.4/BA.5 was significantly decreased. Six months after the first dose vaccination, the neutralizing antibody levels significantly declined and were not further enhanced by a second dose. Omicron BA.1-specific T-cell responses were detectable in most convalescent patients and were not significantly affected by vaccination. These analyses provide insights into the durability of the immune response after infection and hybrid immunization and may be relevant for future vaccine strategies.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"27 ","pages":"Article 100718"},"PeriodicalIF":2.2,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145107624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 and influenza vaccination among adults stably engaged in HIV care","authors":"Grazia Alessio ,&nbsp;Drieda Zaçe ,&nbsp;Christopher Jones ,&nbsp;Andrea Di Lorenzo ,&nbsp;Alessandra Imeneo ,&nbsp;Vincenzo Malagnino ,&nbsp;Elisabetta Teti ,&nbsp;Loredana Sarmati ,&nbsp;Alessandra Ruggiero ,&nbsp;Marco Iannetta ,&nbsp;Anna Maria Geretti ,&nbsp;EVAN-CoV-Study Group","doi":"10.1016/j.jvacx.2025.100719","DOIUrl":"10.1016/j.jvacx.2025.100719","url":null,"abstract":"<div><h3>Introduction</h3><div>Vaccination against COVID-19 and influenza is recommended for people living with HIV, but real-world uptake data remain incomplete, especially in populations facing socioeconomic barriers. We assessed uptake and associated factors at an HIV outpatient centre serving a socioeconomically disadvantaged area of Rome. Participants were in stable HIV care and were encouraged to receive vaccination at no cost, at a location of choice. COVID-19 vaccination was initially available both on-site and externally; influenza vaccination was only available externally.</div></div><div><h3>Methods</h3><div>We analysed a random 50 % sample of 750 adults, retrieving data from the vaccination registry and medical records. Full COVID-19 vaccination was defined as primary vaccination plus <span><math><mo>≥</mo></math></span>1 additional dose. Logistic regression identified factors associated with uptake.</div></div><div><h3>Results</h3><div>Between December 2020 and July 2024, 331/375 (88.3 %) participants received primary COVID-19 vaccination (typically two mRNA vaccine doses 3–4 weeks apart) and 286/375 (76.3 %) received ≥1 additional dose, with most vaccinations occurring before September 2023. Odds of full vaccination were lower among participants &lt;50 years and heterosexual men and women (vs. men who have sex with men). Other associated factors included migrant background, injecting drug use, history of advanced immunosuppression, HIV viraemia, and CD4 &lt;500 cells/mm³. Influenza vaccination uptake (2022/2023) was low (99/375, 26.4 %), although almost 4-fold higher among those vaccinated against COVID-19.</div></div><div><h3>Conclusions</h3><div>Disparities in COVID-19 vaccine coverage and suboptimal influenza vaccination uptake persist among adults stably engaged in HIV care. Addressing barriers, particularly in those with additional vulnerabilities, and integrating vaccination into HIV services may improve uptake and reduce preventable illness.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"27 ","pages":"Article 100719"},"PeriodicalIF":2.2,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145050301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HPV knowledge, vaccination uptake, and information access among adolescents aged 15–19 in France","authors":"Priscille Dumortier ,&nbsp;Élise Frain ,&nbsp;Nathan Peiffer-Smadja","doi":"10.1016/j.jvacx.2025.100717","DOIUrl":"10.1016/j.jvacx.2025.100717","url":null,"abstract":"<div><h3>Introduction</h3><div>Sexual health information for young people is a global public health issue. HPV is the most common sexually transmitted infection. In France, vaccination was extended to girls and in 2019, but coverage remains low<strong>.</strong> This study assessed knowledge about HPV, vaccination, means of protection, and sources of information among adolescents, and analyzed predictors of vaccination.</div></div><div><h3>Method</h3><div>This was an observational cross-sectional survey among girls and boys aged 15–19 in six secondary schools in France. The study was carried out as part of the mandatory health promotion program for third-year medical students.</div></div><div><h3>Results</h3><div>All 357 questionnaires were completed (100 % response rate). Girls were more likely to be informed about HPV than boys, with 67 % (159/238) of girls reporting prior information compared with 44 % (52/119) of boys (<em>p</em> &lt; 0.001). Vaccination uptake was higher among girls, with 40 % (95/238) vaccinated compared with 21 % (25/119) of boys (<em>p</em> &lt; 0.001). Vaccination was significantly more frequent in schools with a higher social position score (<em>p</em> &lt; 0.01). Overall knowledge about HPV was low without significant differences by gender, age, or school. Only 179/357 (50 %) adolescents knew that both girls and boys are affected by HPV, and only 218/357 (61 %) cited vaccination as protection. Social networks were the preferred means of communication about HPV for young people (270/357, 76 %), followed by advertisements on television or public transport (145/357, 41 %).</div></div><div><h3>Conclusion</h3><div>General practitioners play a central role in informing young people about sexual health and HPV. Promoting information through social networks and public campaigns, seldom used for HPV, was encouraged by high school students.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"26 ","pages":"Article 100717"},"PeriodicalIF":2.2,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145007714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}